Cargando…

Fully-automated production of [(68)Ga]Ga-FAPI-46 for clinical application

BACKGROUND: [(68)Ga]Ga-FAPI-46 is a promising radiopharmaceutical for in vivo detection of the fibroblast activation protein by positron emission tomography. Until now, the synthesis of [(68)Ga]Ga-FAPI-46 has been only performed manually. Our aim was to evaluate the automated synthesis of this radio...

Descripción completa

Detalles Bibliográficos
Autores principales: Spreckelmeyer, Sarah, Balzer, Matthias, Poetzsch, Simon, Brenner, Winfried
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746794/
https://www.ncbi.nlm.nih.gov/pubmed/33331982
http://dx.doi.org/10.1186/s41181-020-00112-x
_version_ 1783624865210695680
author Spreckelmeyer, Sarah
Balzer, Matthias
Poetzsch, Simon
Brenner, Winfried
author_facet Spreckelmeyer, Sarah
Balzer, Matthias
Poetzsch, Simon
Brenner, Winfried
author_sort Spreckelmeyer, Sarah
collection PubMed
description BACKGROUND: [(68)Ga]Ga-FAPI-46 is a promising radiopharmaceutical for in vivo detection of the fibroblast activation protein by positron emission tomography. Until now, the synthesis of [(68)Ga]Ga-FAPI-46 has been only performed manually. Our aim was to evaluate the automated synthesis of this radiopharmaceutical on two different commercially available synthesis modules in order to make the tracer readily available for clinical application. RESULTS: The synthesis of [(68)Ga]Ga-FAPI-46 with different amounts of precursor (10–50 μg) on the Modular Lab PharmTracer (MLPT) and Modular Lab eazy (ML eazy) from Eckert & Ziegler with a customized synthesis template and a customized single-use cassette yielded best results with 50 μg FAPI-46 for clinical multi-dose application. All relevant quality control parameters tested (e.g. sterility, stability and radiochemical purity) were in accordance with the European Pharmacopoeia. CONCLUSIONS: [(68)Ga]Ga-FAPI-46 was successfully synthesized fully-automated on the synthesis modules Modular Lab PharmTracer and ML eazy and is, thus, available for multi-dose application in clinical settings.
format Online
Article
Text
id pubmed-7746794
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-77467942020-12-28 Fully-automated production of [(68)Ga]Ga-FAPI-46 for clinical application Spreckelmeyer, Sarah Balzer, Matthias Poetzsch, Simon Brenner, Winfried EJNMMI Radiopharm Chem Research Article BACKGROUND: [(68)Ga]Ga-FAPI-46 is a promising radiopharmaceutical for in vivo detection of the fibroblast activation protein by positron emission tomography. Until now, the synthesis of [(68)Ga]Ga-FAPI-46 has been only performed manually. Our aim was to evaluate the automated synthesis of this radiopharmaceutical on two different commercially available synthesis modules in order to make the tracer readily available for clinical application. RESULTS: The synthesis of [(68)Ga]Ga-FAPI-46 with different amounts of precursor (10–50 μg) on the Modular Lab PharmTracer (MLPT) and Modular Lab eazy (ML eazy) from Eckert & Ziegler with a customized synthesis template and a customized single-use cassette yielded best results with 50 μg FAPI-46 for clinical multi-dose application. All relevant quality control parameters tested (e.g. sterility, stability and radiochemical purity) were in accordance with the European Pharmacopoeia. CONCLUSIONS: [(68)Ga]Ga-FAPI-46 was successfully synthesized fully-automated on the synthesis modules Modular Lab PharmTracer and ML eazy and is, thus, available for multi-dose application in clinical settings. Springer International Publishing 2020-12-17 /pmc/articles/PMC7746794/ /pubmed/33331982 http://dx.doi.org/10.1186/s41181-020-00112-x Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Spreckelmeyer, Sarah
Balzer, Matthias
Poetzsch, Simon
Brenner, Winfried
Fully-automated production of [(68)Ga]Ga-FAPI-46 for clinical application
title Fully-automated production of [(68)Ga]Ga-FAPI-46 for clinical application
title_full Fully-automated production of [(68)Ga]Ga-FAPI-46 for clinical application
title_fullStr Fully-automated production of [(68)Ga]Ga-FAPI-46 for clinical application
title_full_unstemmed Fully-automated production of [(68)Ga]Ga-FAPI-46 for clinical application
title_short Fully-automated production of [(68)Ga]Ga-FAPI-46 for clinical application
title_sort fully-automated production of [(68)ga]ga-fapi-46 for clinical application
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746794/
https://www.ncbi.nlm.nih.gov/pubmed/33331982
http://dx.doi.org/10.1186/s41181-020-00112-x
work_keys_str_mv AT spreckelmeyersarah fullyautomatedproductionof68gagafapi46forclinicalapplication
AT balzermatthias fullyautomatedproductionof68gagafapi46forclinicalapplication
AT poetzschsimon fullyautomatedproductionof68gagafapi46forclinicalapplication
AT brennerwinfried fullyautomatedproductionof68gagafapi46forclinicalapplication